ImmunityBio Inc [IBRX] stock is trading at $2.94, down -3.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The IBRX shares have gain 21.49% over the last week, with a monthly amount drifted -3.92%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on January 10, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $6. Previously, Piper Sandler downgraded its rating to Neutral on May 12, 2023, and dropped its price target to $4. On August 03, 2022, Jefferies initiated with a Buy rating and assigned a price target of $8 on the stock.
ImmunityBio Inc [IBRX] stock has fluctuated between $2.28 and $10.53 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $2.94 at the most recent close of the market. An investor can expect a potential return of 104.08% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
ImmunityBio Inc [NASDAQ:IBRX] reported sales of 7.33M for the trailing twelve months, which represents a growth of 7346.34%. Gross Profit Margin for this corporation currently stands at -0.24% with Operating Profit Margin at -49.0%, Pretax Profit Margin comes in at -80.19%, and Net Profit Margin reading is -80.17%. To continue investigating profitability, this company’s Return on Assets is posted at -1.61, Equity is 0.86 and Total Capital is -1.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.81 points at the first support level, and at 2.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.18, and for the 2nd resistance point, it is at 3.43.
Ratios To Look Out For
For context, ImmunityBio Inc’s Current Ratio is 2.68. On the other hand, the Quick Ratio is 2.64, and the Cash Ratio is 1.84. Considering the valuation of this stock, the price to sales ratio is 292.86.
